Virax Biolabs Group Stock Market Value
| VRAX Stock | USD 1.90 0.02 1.06% |
| Symbol | Virax |
Virax Biolabs Group Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Virax Biolabs. If investors know Virax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Virax Biolabs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
The market value of Virax Biolabs Group is measured differently than its book value, which is the value of Virax that is recorded on the company's balance sheet. Investors also form their own opinion of Virax Biolabs' value that differs from its market value or its book value, called intrinsic value, which is Virax Biolabs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Virax Biolabs' market value can be influenced by many factors that don't directly affect Virax Biolabs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Virax Biolabs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Virax Biolabs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Virax Biolabs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Virax Biolabs 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Virax Biolabs' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Virax Biolabs.
| 01/17/2025 |
| 02/16/2025 |
If you would invest 0.00 in Virax Biolabs on January 17, 2025 and sell it all today you would earn a total of 0.00 from holding Virax Biolabs Group or generate 0.0% return on investment in Virax Biolabs over 30 days. Virax Biolabs is related to or competes with Revelation Biosciences, Kiora Pharmaceuticals, Quoin Pharmaceuticals, Cardio Diagnostics, Allarity Therapeutics, Biodexa Pharmaceticals, and Unicycive Therapeutics. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tec... More
Virax Biolabs Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Virax Biolabs' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Virax Biolabs Group upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.22 | |||
| Information Ratio | 0.0335 | |||
| Maximum Drawdown | 59.66 | |||
| Value At Risk | (11.20) | |||
| Potential Upside | 19.9 |
Virax Biolabs Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virax Biolabs' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Virax Biolabs' standard deviation. In reality, there are many statistical measures that can use Virax Biolabs historical prices to predict the future Virax Biolabs' volatility.| Risk Adjusted Performance | 0.0338 | |||
| Jensen Alpha | 0.3242 | |||
| Total Risk Alpha | 0.3064 | |||
| Sortino Ratio | 0.0443 | |||
| Treynor Ratio | (0.12) |
Virax Biolabs Group Backtested Returns
Virax Biolabs appears to be risky, given 3 months investment horizon. Virax Biolabs Group owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0444, which indicates the firm had a 0.0444 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Virax Biolabs Group, which you can use to evaluate the volatility of the company. Please review Virax Biolabs' Risk Adjusted Performance of 0.0338, coefficient of variation of 2881.58, and Semi Deviation of 6.91 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Virax Biolabs holds a performance score of 3. The entity has a beta of -2.62, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Virax Biolabs are expected to decrease by larger amounts. On the other hand, during market turmoil, Virax Biolabs is expected to outperform it. Please check Virax Biolabs' semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether Virax Biolabs' existing price patterns will revert.
Auto-correlation | -0.66 |
Very good reverse predictability
Virax Biolabs Group has very good reverse predictability. Overlapping area represents the amount of predictability between Virax Biolabs time series from 17th of January 2025 to 1st of February 2025 and 1st of February 2025 to 16th of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Virax Biolabs Group price movement. The serial correlation of -0.66 indicates that around 66.0% of current Virax Biolabs price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.66 | |
| Spearman Rank Test | -0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Virax Biolabs Group lagged returns against current returns
Autocorrelation, which is Virax Biolabs stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Virax Biolabs' stock expected returns. We can calculate the autocorrelation of Virax Biolabs returns to help us make a trade decision. For example, suppose you find that Virax Biolabs has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Virax Biolabs regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Virax Biolabs stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Virax Biolabs stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Virax Biolabs stock over time.
Current vs Lagged Prices |
| Timeline |
Virax Biolabs Lagged Returns
When evaluating Virax Biolabs' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Virax Biolabs stock have on its future price. Virax Biolabs autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Virax Biolabs autocorrelation shows the relationship between Virax Biolabs stock current value and its past values and can show if there is a momentum factor associated with investing in Virax Biolabs Group.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.